The rate of cancer treatment-related cardiac events was 14.9% in patients who received osimertinib and 4.4% in patients who received other EGFR tyrosine kinase inhibitors. Patients with EGFR-mutant ...
The rate of cancer treatment-related cardiac events was 14.9% in patients who received osimertinib and 4.4% in patients who received other EGFR tyrosine kinase inhibitors. Patients with EGFR ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback